Theratechnologies Secures US Patent for its Novel Peptide TH1173

Theratechnologies Secures US Patent for its Novel Peptide TH1173 
MONTREAL, CANADA -- (Marketwire) -- 01/29/13 -- Theratechnologies
Inc. (TSX:TH)(NASDAQ:THER) today reported that the US Patent and
Trademark Office (USPTO) has granted a patent (US Patent No.
8,361,964) for its second generation growth-hormone releasing factor
(GRF) peptide, TH1173, providing for patent protection beyond 2030.  
"While we are currently focusing all of our efforts and resources on
revenue growth from tesamorelin as per our revised business plan, we
still firmly believe in the long-term potential of TH1173. With this
patent in place, we now have a secure timeframe during which we will
be able to explore partnerships and licensing activities in certain
territories to tap into this potential in the future," stated Luc
Tanguay, President and Chief Executive Officer of Theratechnologies. 
The preclinical phase for TH1173 is now completed. Results, including
those from seven-day and 28-day toxicology trials, warrant the
pursuit of the clinical stage development at the appropriate time. 
TH1173 is unpartnered and wholly-owned by Theratechnologies. 
About Theratechnologies  
Theratechnologies (TSX:TH)(NASDAQ:THER) is a biopharmaceutical
company that specializes in innovative therapeutic peptide products,
with an emphasis on growth-hormone releasing factor peptides. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on the
Securities and Exchange Commission's website at www.sec.gov.  
Forward-Looking Information  
This press release contains certain statements that are considered
"forward-looking information" within the meaning of applicable
securities legislation, which statements may contain such words as
"may", "would", "could", "will", "intend", "plan", "anticipate",
"believe", "estimate", "expect" and similar expressions. This
forward-looking information includes, but is not limited to,
information regarding the term of our patent, our capacity to grow
our revenues, the medical potential of TH1173, the exploration of
partnerships and licensing opportunities for TH1173 in certain
territories and the pursuit of the clinical development of TH1173 at
the appropriate time. 
Forward-looking information is based upon a number of assumptions and
is subject to a number of risks and uncertainties, many of which are
beyond Theratechnologies' control that could cause actual results to
differ materially from those that are disclosed in or implied by such
forward-looking information. These assumptions include, but are not
limited to, the fact that we will be successful in defending the
validity and enforceability of our patent in the event it is
challenged by a third party, that tesamorelin for the treatment of
excess abdominal fat in HIV-infected patients with lipodystrophy will
be approved, and, once approved, accepted by the marketplace, in
jurisdictions where marketing authorization applications are pending,
that we will succeed in resubmitting a marketing authorization
application (MAA) for tesamorelin in Europe and that the MAA will be
approved by European regulatory authorities, that we will have the
human and financial resources, skills and know-how to pursue the
development of TH1173 and that results from such research will be
positive and allow us to continue the development of TH1173, and that
third parties will be interested in entering into partnership or
licensing agreements for TH1173 on commercial terms acceptable to us.
These risks and uncertainties include, but are not limited to, the
risk that we are unable to successfully defend the validity and
enforceability of our patent in the event it is challenged by a third
party, the risk that some or all of the pending marketing
authorization applications for tesamorelin are not approved or that,
if approved, the marketplace in the jurisdictions where approval is
obtained do not accept the product, the risk that we are unable to
resubmit an MAA for tesamorelin in Europe, the risk that we do not
have, or lose, the necessary resources, skills and know-how to pursue
the development of TH1173 or that results from further research on
TH1173 do not warrant the pursuit of further development, and the
risk that no third party is interested in entering into partnership
or licensing agreements with us regarding TH1173 or that the terms of
such agreements are not commercially acceptable to us. 
Theratechnologies refers potential investors to the "Risks Factors"
section of its Annual Information Form (AIF) dated February 27, 2012.
The AIF is available at www.sedar.com and at www.sec.gov under
Theratechnologies' public filings. The reader is cautioned to
consider these and other risks and uncertainties carefully and not to
put undue reliance on forward-looking statements. Forward-looking
information reflects current expectations regarding future events and
speaks only as of the date of this press release and represents
Theratechnologies' expectations as of that date. 
Theratechnologies undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise, except
as may be required by applicable law.
Contacts:
Denis Boucher
NATIONAL Public Relations
514-843-2393